… non-cancerous drugs with anticancer activity… drug repurposing and the combination of
micronutrients that can target both cancers and cancer stem cells may result in a better therapeutic …

… current data supporting drug repurposing as a … drug repurposing as a feasible option for
patients with CRC with a focus on the evidence and mechanism of action promising repurposed …

… non-oncology drugs for clinical cancer management and classify these candidates into their
… - or drug combination therapy. We also summarize approaches used for drug repurposing …

… While novel drug development is unfavorable in terms of time frame and costs, drug
repurposing is one of the promising strategies to combat resistance. This approach refers to the …

… discovery and the development of bacterial resistance. We summarize drug-drug interactions
and uncover the art of repurposing non-antibiotic drugs as potential antibiotic adjuvants, …

… vitro antimicrobial activity to support existing anti-infective therapeutics is provided, including
several critical remarks on this strategy of repurposing non-antibiotics to antibacterial drugs. …

… , affecting stromal, endothelial, and immune cells, as well as promoting epithelial-to-mesenchymal
transition, which is believed to be a contributor to therapy resistance in PCa [20,21]. …

… may make them suitable to be repurposed as cancer therapeutics (Fig. 1). This review article
also includes the clinical trial status of repurposed drugs, which are currently being focused …

… resistance represents a major challenge for cancer treatment. In the search for new
chemotherapeutics to treat malignant diseases, drug repurposing … for cancer therapeutics. These …

… in 2014, our group performed a drug repurposing screen which identified a set of 53
Ebola-entry inhibitors [45]. However, the human plasma drug concentrations of most of these …